{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:10:26Z","timestamp":1761333026531,"version":"build-2065373602"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10787-025-01921-9","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T09:08:15Z","timestamp":1758618495000},"page":"5977-5994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting mGluR7 in Parkinson\u2019s disease: a novel approach to neuroprotection and synaptic therapies"],"prefix":"10.1007","volume":"33","author":[{"given":"Gursimran","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-2975","authenticated-orcid":false,"given":"Khadga Raj","family":"Aran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"1921_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coph.2014.11.001","volume":"20","author":"M Amalric","year":"2015","unstructured":"Amalric M (2015) Targeting metabotropic glutamate receptors (mGluRs) in Parkinson\u2019s disease. Curr Opin Pharmacol 20:29\u201334. https:\/\/doi.org\/10.1016\/j.coph.2014.11.001","journal-title":"Curr Opin Pharmacol"},{"key":"1921_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/bs.apha.2020.03.001","volume":"88","author":"KA Bennett","year":"2020","unstructured":"Bennett KA, Christopher JA, Tehan BG (2020) Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators. Adv Pharmacol 88:35\u201358. https:\/\/doi.org\/10.1016\/bs.apha.2020.03.001","journal-title":"Adv Pharmacol"},{"key":"1921_CR3","unstructured":"Beske PH (2012) The role of NADPH oxidase in ischemia\/reperfusion-induced alterations to AMPA receptor trafficking and NMDA receptor function. PhD thesis, University of Montana"},{"issue":"1","key":"1921_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1570159X17666190618121859","volume":"18","author":"S Boccella","year":"2020","unstructured":"Boccella S, Marabese I, Guida F, Luongo L, Maione S, Palazzo E (2020) The modulation of pain by metabotropic glutamate receptors 7 and 8 in the dorsal striatum. Curr Neuropharmacol 18(1):34\u201350. https:\/\/doi.org\/10.2174\/1570159X17666190618121859","journal-title":"Curr Neuropharmacol"},{"issue":"4b","key":"1921_CR5","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/j.1476-5381.2011.01515.x","volume":"165","author":"M Broadstock","year":"2012","unstructured":"Broadstock M, Austin PJ, Betts MJ, Duty S (2012) Antiparkinsonian potential of targeting group III metabotropic glutamate receptor subtypes in the rodent substantia nigra pars reticulata. Br J Pharmacol 165(4b):1034\u20131045. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01515.x","journal-title":"Br J Pharmacol"},{"key":"1921_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2022.105697","volume":"168","author":"F Campanelli","year":"2022","unstructured":"Campanelli F, Natale G, Marino G, Ghiglieri V, Calabresi P (2022) Striatal glutamatergic hyperactivity in Parkinson\u2019s disease. Neurobiol Dis 168:105697. https:\/\/doi.org\/10.1016\/j.nbd.2022.105697","journal-title":"Neurobiol Dis"},{"issue":"3","key":"1921_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.baga.2013.09.001","volume":"3","author":"P Carrillo-Mora","year":"2013","unstructured":"Carrillo-Mora P, Silva-Adaya D, Villase\u00f1or-Aguayo K (2013) Glutamate in Parkinson\u2019s disease: role of antiglutamatergic drugs. Basal Ganglia 3(3):147\u2013157. https:\/\/doi.org\/10.1016\/j.baga.2013.09.001","journal-title":"Basal Ganglia"},{"issue":"12","key":"1921_CR8","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/j.neuron.2022.03.015","volume":"110","author":"XT Cheng","year":"2022","unstructured":"Cheng XT, Huang N, Sheng ZH (2022) Programming axonal mitochondrial maintenance and bioenergetics in neurodegeneration and regeneration. Neuron 110(12):1899\u20131923. https:\/\/doi.org\/10.1016\/j.neuron.2022.03.015","journal-title":"Neuron"},{"issue":"5","key":"1921_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4274\/balkanmedj.galenos.2022.2022-7-100","volume":"39","author":"E \u00c7\u0131nar","year":"2022","unstructured":"\u00c7\u0131nar E, Tel BC, \u015eahin G (2022) Neuroinflammation in Parkinson\u2019s disease and its treatment opportunities. Balkan Med J 39(5):318. https:\/\/doi.org\/10.4274\/balkanmedj.galenos.2022.2022-7-100","journal-title":"Balkan Med J"},{"key":"1921_CR10","unstructured":"ClinicalTrials.gov. Study of Drug X in Parkinson\u2019s Disease (NCT03998787). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03998787 . Accessed July 30, 2025."},{"key":"1921_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fnmol.2019.00020","volume":"12","author":"R Crupi","year":"2019","unstructured":"Crupi R, Impellizzeri D, Cuzzocrea S (2019) Role of metabotropic glutamate receptors in neurological disorders. Front Mol Neurosci 12:20. https:\/\/doi.org\/10.3389\/fnmol.2019.00020","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"1921_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1046\/j.1460-9568.2002.01919.x","volume":"15","author":"HN David","year":"2002","unstructured":"David HN, Abraini JH (2002) Group III metabotropic glutamate receptors and D1-like and D2-like dopamine receptors interact in the rat nucleus accumbens to influence locomotor activity. Eur J Neurosci 15(5):869\u2013875. https:\/\/doi.org\/10.1046\/j.1460-9568.2002.01919.x","journal-title":"Eur J Neurosci"},{"key":"1921_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/978-3-319-42139-1_2","volume-title":"Mitochondrial mechanisms of degeneration and repair in Parkinson's disease","author":"S Delcambre","year":"2016","unstructured":"Delcambre S, Nonnenmacher Y, Hiller K (2016) Dopamine metabolism and reactive oxygen species production. In: Buhlman L (ed) Mitochondrial mechanisms of degeneration and repair in Parkinson\u2019s disease. Springer, Cham, pp 25\u201347. https:\/\/doi.org\/10.1007\/978-3-319-42139-1_2"},{"key":"1921_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2022.173452","volume":"219","author":"H Domin","year":"2022","unstructured":"Domin H (2022) Group III metabotropic glutamate receptors as promising targets for neuroprotective therapy: Particular emphasis on the role of mGlu4 and mGlu7 receptors. Pharmacol Biochem Behav 219:173452. https:\/\/doi.org\/10.1016\/j.pbb.2022.173452","journal-title":"Pharmacol Biochem Behav"},{"issue":"6","key":"1921_CR15","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s43440-024-00657-7","volume":"76","author":"H Domin","year":"2024","unstructured":"Domin H, Burnat G (2024) MGlu4R, mGlu7R, and mGlu8R allosteric modulation for treating acute and chronic neurodegenerative disorders. Pharmacol Rep 76(6):1219\u20131241. https:\/\/doi.org\/10.1007\/s43440-024-00657-7","journal-title":"Pharmacol Rep"},{"key":"1921_CR16","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fnmol.2018.00387","volume":"11","author":"NM Fisher","year":"2018","unstructured":"Fisher NM, Seto M, Lindsley CW, Niswender CM (2018) Metabotropic glutamate receptor 7: a new therapeutic target in neurodevelopmental disorders. Front Mol Neurosci 11:387. https:\/\/doi.org\/10.3389\/fnmol.2018.00387","journal-title":"Front Mol Neurosci"},{"key":"1921_CR17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-1-4615-0123-7_7","volume-title":"Molecular and cellular biology of neuroprotection in the CNS","author":"PJ Flor","year":"2003","unstructured":"Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V (2003) Neuroprotective activity of metabotropic glutamate receptor ligands. In: Wouters R, Vandesande F, De Deyn PP (eds) Molecular and cellular biology of neuroprotection in the CNS. Springer, Cham, pp 197\u2013223"},{"issue":"13","key":"1921_CR18","doi-asserted-by":"publisher","first-page":"10265","DOI":"10.1074\/jbc.M111.325175","volume":"287","author":"Z Gu","year":"2012","unstructured":"Gu Z, Liu W, Wei J, Yan Z (2012) Regulation of N-methyl-D-aspartic acid (NMDA) receptors by metabotropic glutamate receptor 7. J Biol Chem 287(13):10265\u201310275. https:\/\/doi.org\/10.1074\/jbc.M111.325175","journal-title":"J Biol Chem"},{"key":"1921_CR19","doi-asserted-by":"publisher","first-page":"175628642513398","DOI":"10.1177\/17562864251339895","volume":"18","author":"L Guan","year":"2025","unstructured":"Guan L, Lin L, Ma C, Qiu L (2025) Decoding crosstalk between neurotransmitters and \u03b1-synuclein in Parkinson\u2019s disease: pathogenesis and therapeutic implications. Ther Adv Neurol Disord 18:17562864251339896. https:\/\/doi.org\/10.1177\/17562864251339895","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"1921_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.pneurobio.2004.09.001","volume":"74","author":"P Gubellini","year":"2004","unstructured":"Gubellini P, Pisani A, Centonze D, Bernardi G, Calabresi P (2004) Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog Neurobiol 74(5):271\u2013300. https:\/\/doi.org\/10.1016\/j.pneurobio.2004.09.001","journal-title":"Prog Neurobiol"},{"issue":"3","key":"1921_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3390\/biom15030392","volume":"15","author":"BM Gyetvai","year":"2025","unstructured":"Gyetvai BM, Vadasz C (2025) Pleiotropic effects of Grm7\/GRM7 in shaping neurodevelopmental pathways and the neural substrate of complex behaviors and disorders. Biomolecules 15(3):392. https:\/\/doi.org\/10.3390\/biom15030392","journal-title":"Biomolecules"},{"issue":"7","key":"1921_CR22","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tins.2007.05.004","volume":"30","author":"C Hammond","year":"2007","unstructured":"Hammond C, Bergman H, Brown P (2007) Pathological synchronization in Parkinson\u2019s disease: networks, models and treatments. Trends Neurosci 30(7):357\u2013364. https:\/\/doi.org\/10.1016\/j.tins.2007.05.004","journal-title":"Trends Neurosci"},{"issue":"2","key":"1921_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3233\/BPL-210120","volume":"7","author":"PU H\u00e1mor","year":"2021","unstructured":"H\u00e1mor PU, Schwendt M (2021) Metabotropic glutamate receptor trafficking and its role in drug-induced neurobehavioral plasticity. Brain Plast 7(2):61\u201376. https:\/\/doi.org\/10.3233\/BPL-210120","journal-title":"Brain Plast"},{"key":"1921_CR24","doi-asserted-by":"publisher","DOI":"10.1152\/jn.00897.2012","author":"JL Hauser","year":"2012","unstructured":"Hauser JL, Edson EB, Hooks BM, Chen C (2012) Articles in PresS. J Neurophysiol. https:\/\/doi.org\/10.1152\/jn.00897.2012","journal-title":"J Neurophysiol"},{"issue":"10","key":"1921_CR25","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/mds.29558","volume":"38","author":"Y Hu","year":"2023","unstructured":"Hu Y, Ma TC, Alberico SL, Ding Y, Jin L, Kang UJ (2023) Substantia nigra pars reticulata projections to the pedunculopontine nucleus modulate dyskinesia. Mov Disord 38(10):1850\u20131860. https:\/\/doi.org\/10.1002\/mds.29558","journal-title":"Mov Disord"},{"key":"1921_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01765-3","author":"G Hunjan","year":"2025","unstructured":"Hunjan G, Aran KR (2025) Role of mGluR7 in Alzheimer\u2019s disease: pathophysiological insights and therapeutic approaches. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-025-01765-3","journal-title":"Inflammopharmacology"},{"issue":"3","key":"1921_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L (2020) Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci 144(3):151\u2013164. https:\/\/doi.org\/10.1016\/j.jphs.2020.07.011","journal-title":"J Pharmacol Sci"},{"issue":"7","key":"1921_CR28","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/cells12071012","volume":"12","author":"S Isik","year":"2023","unstructured":"Isik S, Yeman Kiyak B, Akbayir R, Seyhali R, Arpaci T (2023) Microglia mediated neuroinflammation in Parkinson\u2019s disease. Cells 12(7):1012. https:\/\/doi.org\/10.3390\/cells12071012","journal-title":"Cells"},{"issue":"12","key":"1921_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1021\/cn500153z","volume":"5","author":"N Jalan-Sakrikar","year":"2014","unstructured":"Jalan-Sakrikar N, Field JR, Klar R, Mattmann ME, Gregory KJ, Zamorano R, Engers DW, Bollinger SR, Weaver CD, Days EL, Lewis LM (2014) Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7. ACS Chem Neurosci 5(12):1221\u20131237. https:\/\/doi.org\/10.1021\/cn500153z","journal-title":"ACS Chem Neurosci"},{"issue":"4","key":"1921_CR30","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J (2008) Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 79(4):368\u2013376. https:\/\/doi.org\/10.1136\/jnnp.2007.131045","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1921_CR31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.neuropharm.2018.08.035","volume":"141","author":"D Jantas","year":"2018","unstructured":"Jantas D, Lech T, Go\u0142da S, Pilc A, Laso\u0144 W (2018) New evidences for a role of mGluR7 in astrocyte survival: possible implications for neuroprotection. Neuropharmacology 141:223\u2013237. https:\/\/doi.org\/10.1016\/j.neuropharm.2018.08.035","journal-title":"Neuropharmacology"},{"issue":"12","key":"1921_CR32","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.drudis.2018.08.001","volume":"23","author":"K Kalani","year":"2018","unstructured":"Kalani K, Yan SF, Yan SS (2018) Mitochondrial permeability transition pore: a potential drug target for neurodegeneration. Drug Discov Today 23(12):1983\u20131989. https:\/\/doi.org\/10.1016\/j.drudis.2018.08.001","journal-title":"Drug Discov Today"},{"issue":"5","key":"1921_CR33","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/S1734-1140(13)71477-4","volume":"65","author":"J Konieczny","year":"2013","unstructured":"Konieczny J, Lenda T (2013) Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: a behavioral study with the selective agonist AMN082. Pharmacol Rep 65(5):1194\u20131203. https:\/\/doi.org\/10.1016\/S1734-1140(13)71477-4","journal-title":"Pharmacol Rep"},{"key":"1921_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/bs.apcsb.2015.10.004","volume":"103","author":"K Lee","year":"2016","unstructured":"Lee K, Goodman L, Fourie C, Schenk S, Leitch B, Montgomery JM (2016) AMPA receptors as therapeutic targets for neurological disorders. Adv Protein Chem Struct Biol 103:203\u2013261. https:\/\/doi.org\/10.1016\/bs.apcsb.2015.10.004","journal-title":"Adv Protein Chem Struct Biol"},{"key":"1921_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102554","volume":"102","author":"P Li","year":"2024","unstructured":"Li P, Lei W, Dong Y, Wang X, Ye X, Tian Y, Yang Y, Liu J, Li N, Niu X, Wang X (2024a) mGluR7: the new player protecting the central nervous system. Ageing Res Rev 102:102554. https:\/\/doi.org\/10.1016\/j.arr.2024.102554","journal-title":"Ageing Res Rev"},{"key":"1921_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102554","volume":"102","author":"P Li","year":"2024","unstructured":"Li P, Lei W, Dong Y, Wang X, Ye X, Tian Y et al (2024b) MGluR7: the new player protecting the central nervous system. Ageing Res Rev 102:102554. https:\/\/doi.org\/10.1016\/j.arr.2024.102554","journal-title":"Ageing Res Rev"},{"issue":"11","key":"1921_CR37","doi-asserted-by":"publisher","first-page":"6707","DOI":"10.1021\/acs.chemrev.5b00656","volume":"116","author":"CW Lindsley","year":"2016","unstructured":"Lindsley CW, Emmitte KA, Hopkins CR, Bridges TM, Gregory KJ, Niswender CM, Conn PJ (2016) Practical strategies and concepts in GPCR allosteric modulator discovery: recent advances with metabotropic glutamate receptors. Chem Rev 116(11):6707\u20136741. https:\/\/doi.org\/10.1021\/acs.chemrev.5b00656","journal-title":"Chem Rev"},{"key":"1921_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.neuropharm.2016.03.036","volume":"115","author":"N Litim","year":"2017","unstructured":"Litim N, Morissette M, Di Paolo T (2017) Metabotropic glutamate receptors as therapeutic targets in Parkinson\u2019s disease: an update from the last 5 years of research. Neuropharmacology 115:166\u2013179. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.03.036","journal-title":"Neuropharmacology"},{"key":"1921_CR39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.coph.2018.03.004","volume":"38","author":"GJ Masilamoni","year":"2018","unstructured":"Masilamoni GJ, Smith Y (2018) Metabotropic glutamate receptors: targets for neuroprotective therapies in Parkinson disease. Curr Opin Pharmacol 38:72\u201380. https:\/\/doi.org\/10.1016\/j.coph.2018.03.004","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"1921_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","volume":"47","author":"LT May","year":"2007","unstructured":"May LT, Leach K, Sexton PM, Christopoulos A (2007) Allosteric modulation of G protein\u2013coupled receptors. Annu Rev Pharmacol Toxicol 47(1):1\u201351. https:\/\/doi.org\/10.1146\/annurev.pharmtox.47.120505.105159","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1921_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","volume":"50","author":"CM Niswender","year":"2010","unstructured":"Niswender CM, Conn PJ (2010a) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295\u2013322. https:\/\/doi.org\/10.1146\/annurev.pharmtox.011008.145533","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"1921_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","volume":"50","author":"CM Niswender","year":"2010","unstructured":"Niswender CM, Conn PJ (2010b) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50(1):295\u2013322. https:\/\/doi.org\/10.1146\/annurev.pharmtox.011008.145533","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"1921_CR43","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/(SICI)1096-9861(19991213)415:2<266::AID-CNE9>3.0.CO;2-7","volume":"415","author":"CM Osinski","year":"1999","unstructured":"Osinski CM, Risso Bradley S, Conn PJ, Levey AI, Landwehrmeyer GB, Penney JB Jr, Young AB, Standaert DG (1999) Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia. J Comp Neurol 415(2):266\u2013284","journal-title":"J Comp Neurol"},{"issue":"5","key":"1921_CR44","doi-asserted-by":"publisher","first-page":"504","DOI":"10.2174\/1570159X13666150716165323","volume":"14","author":"E Palazzo","year":"2016","unstructured":"Palazzo E, Marabese I, de Novellis V, Rossi F, Maione S (2016) Metabotropic glutamate receptor 7: from synaptic function to therapeutic implications. Curr Neuropharmacol 14(5):504\u2013513. https:\/\/doi.org\/10.2174\/1570159X13666150716165323","journal-title":"Curr Neuropharmacol"},{"key":"1921_CR45","doi-asserted-by":"publisher","first-page":"100","DOI":"10.37881\/1.331","volume":"10","author":"A Pathan","year":"2018","unstructured":"Pathan A, Alshahrani AM (2018) Gold standard of symptomatic treatment in Parkinson disease: Carbidopa\/Levodopa. Tablet 10:100. https:\/\/doi.org\/10.37881\/1.331","journal-title":"Tablet"},{"key":"1921_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115733","volume":"168","author":"N Rabeh","year":"2023","unstructured":"Rabeh N, Hajjar B, Maraka JO, Sammanasunathan AF, Khan M, Alkhaaldi SM, Mansour S, Almheiri RT, Hamdan H, Abd-Elrahman KS (2023a) Targeting mGluR group III for the treatment of neurodegenerative diseases. Biomed Pharmacother 168:115733","journal-title":"Biomed Pharmacother"},{"key":"1921_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115733","volume":"168","author":"N Rabeh","year":"2023","unstructured":"Rabeh N, Hajjar B, Maraka JO, Sammanasunathan AF, Khan M, Alkhaaldi SM, Mansour S, Almheiri RT, Hamdan H, Abd-Elrahman KS (2023b) Targeting mGluR group III for the treatment of neurodegenerative diseases. Biomed Pharmacother 168:115733. https:\/\/doi.org\/10.1016\/j.biopha.2023.115733","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1921_CR48","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","volume":"10","author":"S Ramesh","year":"2023","unstructured":"Ramesh S, Arachchige AS (2023) Depletion of dopamine in Parkinson\u2019s disease and relevant therapeutic options: a review of the literature. AIMS Neurosci 10(3):200. https:\/\/doi.org\/10.3934\/Neuroscience.2023017","journal-title":"AIMS Neurosci"},{"issue":"11","key":"1921_CR49","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1128\/MCB.25.11.4501-4513.2005","volume":"25","author":"M Velichkova","year":"2005","unstructured":"Velichkova M, Hasson T (2005) Keap1 regulates the oxidation-sensitive shuttling of Nrf2 into and out of the nucleus via a Crm1-dependent nuclear export mechanism. Mol Cell Biol 25(11):4501\u20134513. https:\/\/doi.org\/10.1128\/MCB.25.11.4501-4513.2005","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1921_CR50","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40035-021-00278-7","volume":"11","author":"M Verma","year":"2022","unstructured":"Verma M, Lizama BN, Chu CT (2022) Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl Neurodegener 11(1):3","journal-title":"Transl Neurodegener"},{"issue":"3","key":"1921_CR51","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00702-017-1735-6","volume":"125","author":"RM Villalba","year":"2018","unstructured":"Villalba RM, Smith Y (2018) Loss and remodeling of striatal dendritic spines in Parkinson\u2019s disease: from homeostasis to maladaptive plasticity? J Neural Transm 125(3):431\u2013447. https:\/\/doi.org\/10.1007\/s00702-017-1735-6","journal-title":"J Neural Transm"},{"key":"1921_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejphar.2018.01.038","volume":"823","author":"CC Wang","year":"2018","unstructured":"Wang CC, Kuo JR, Huang SK, Wang SJ (2018) Metabotropic glutamate 7 receptor agonist AMN082 inhibits glutamate release in rat cerebral cortex nerve terminal. Eur J Pharmacol 823:11\u201318. https:\/\/doi.org\/10.1016\/j.ejphar.2018.01.038","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1921_CR53","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jnc.12608","volume":"129","author":"CJ Williams","year":"2014","unstructured":"Williams CJ, Dexter DT (2014) Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease. J Neurochem 129(1):4\u201320. https:\/\/doi.org\/10.1111\/jnc.12608","journal-title":"J Neurochem"},{"issue":"1","key":"1921_CR54","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41392-023-01427-2","volume":"8","author":"TS Wong","year":"2023","unstructured":"Wong TS, Li G, Li S, Gao W, Chen G, Gan S et al (2023) G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduct Target Ther 8(1):177. https:\/\/doi.org\/10.1038\/s41392-023-01427-2","journal-title":"Signal Transduct Target Ther"},{"key":"1921_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01576-w","author":"WL Wu","year":"2025","unstructured":"Wu WL, Gong XX, Qin ZH, Wang Y (2025) Molecular mechanisms of excitotoxicity and their relevance to the pathogenesis of neurodegenerative diseases\u2014an update. Acta Pharmacol Sin. https:\/\/doi.org\/10.1038\/s41401-025-01576-w","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"1921_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031641","volume":"25","author":"J Xue","year":"2024","unstructured":"Xue J, Tao K, Wang W, Wang X (2024) What can inflammation tell us about therapeutic strategies for Parkinson\u2019s disease? Int J Mol Sci 25(3):1641. https:\/\/doi.org\/10.3390\/ijms25031641","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1921_CR57","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cytogfr.2014.09.002","volume":"26","author":"Y Yang","year":"2015","unstructured":"Yang Y, Jiang S, Yan J, Li Y, Xin Z, Lin Y, Qu Y (2015) An overview of the molecular mechanisms and novel roles of Nrf2 in neurodegenerative disorders. Cytokine Growth Factor Rev 26(1):47\u201357. https:\/\/doi.org\/10.1016\/j.cytogfr.2014.09.002","journal-title":"Cytokine Growth Factor Rev"},{"key":"1921_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2024.100808","volume":"39","author":"M Zaki-Dizaji","year":"2024","unstructured":"Zaki-Dizaji M, Abazari MF, Razzaghi H, Shkolnikov I, Christie BR (2024) Grm7 deficiency, from excitotoxicity and neuroinflammation to neurodegeneration: systematic review of GRM7 deficient patients. Brain Behav Immun Health 39:100808. https:\/\/doi.org\/10.1016\/j.bbih.2024.100808","journal-title":"Brain Behav Immun Health"},{"issue":"18","key":"1921_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20184391","volume":"20","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Zhang S, Fu P, Zhang Z, Lin K, Ko JKS, Yung KKL (2019) Roles of glutamate receptors in Parkinson\u2019s disease. Int J Mol Sci 20(18):4391. https:\/\/doi.org\/10.3390\/ijms20184391","journal-title":"Int J Mol Sci"},{"key":"1921_CR60","doi-asserted-by":"publisher","first-page":"1118078","DOI":"10.3389\/fnmol.2023.1118078","volume":"16","author":"C Zhao","year":"2023","unstructured":"Zhao C, Wang C, Zhang H, Yan W (2023) A mini-review of the role of vesicular glutamate transporters in Parkinson\u2019s disease. Front Mol Neurosci 16:1118078. https:\/\/doi.org\/10.3389\/fnmol.2023.1118078","journal-title":"Front Mol Neurosci"},{"issue":"5","key":"1921_CR61","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1074\/jbc.TM118.004163","volume":"294","author":"Z Zurawski","year":"2019","unstructured":"Zurawski Z, Yim YY, Alford S, Hamm HE (2019) The expanding roles and mechanisms of G protein\u2013mediated presynaptic inhibition. J Biol Chem 294(5):1661\u20131670. https:\/\/doi.org\/10.1074\/jbc.TM118.004163","journal-title":"J Biol Chem"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01921-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01921-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01921-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:04:54Z","timestamp":1761332694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01921-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01921-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"type":"print","value":"0925-4692"},{"type":"electronic","value":"1568-5608"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}